Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis

Lu,Jia‑Ju; Guo,Hong; Gao,Bo; Zhang,Yun; Lin,Qing‑Ling; Shi,Jiang; Liu,Jing‑Jing; Liu,Jian

doi:10.3892/mco.2017.1484

Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis

Authors:
- Jia‑Ju Lu
- Hong Guo
- Bo Gao
- Yun Zhang
- Qing‑Ling Lin
- Jiang Shi
- Jing‑Jing Liu
- Jian Liu
View Affiliations

Affiliations: The First Clinical Medical College, Lanzhou, Lanzhou 730000, P.R. China, The First Hospital, Lanzhou University, Lanzhou, Lanzhou 730000, P.R. China
Published online on: November 3, 2017 https://doi.org/10.3892/mco.2017.1484
Pages: 127-132

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current relevant research suggests there are significant differences between the expression of the urokinase plasminogen activator (uPA) system in cancer tissues and in normal tissues. However, the potential effectiveness of the uPA system as a prognostic biomarker of non‑small cell lung cancer (NSCLC) remains unclear. In the present study, a systematic review and meta‑analysis were performed to evaluate the relevance of the uPA system in the prognosis of patients with NSCLC. Using the PubMed, EMBASE, Web of Science and Cochrane Library databases, data from relevant academic journal articles were extracted and subjected to analysis. Associations between expression profiles pertaining to the uPA system and the overall survival (OS) of patients with NSCLC were analyzed. The study incorporated data from 11 independent journal articles and these reports included a total of 937 patients with NSCLC. The meta‑analysis results revealed that increased expression of urokinase plasminogen activator (uPA) and PA inhibitor type 1 (PAI‑1) exhibited no significant association with poor OS [hazard ratio (HR)‑uPA=1.07 (0.87‑1.31), P=0.53; HR‑PAI‑1=1.02 (0.63‑1.65), P=0.94]. Similarly, reduced expression of PAI type 2 (PAI‑2) did not significantly correlate with poor OS [HR‑PAI‑2=1.58 (0.64‑3.90); P=0.32]. Notably, however, a significant association was observed between increased expression levels of uPA receptor (uPAR) and poor OS for NSCLC [HR‑uPAR=1.50 (1.04‑2.15); P=0.03]. Therefore, the expression of uPAR in the uPA system of patients with NSCLC could be used as a novel clinical biomarker to evaluate the prognosis of NSCLC. The utilization of this biomarker may provide a platform for the further development of targeted drugs for the treatment of NSCLC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ben Amar J, Ben Safta B, Zaibi H, Dhahri B, Baccar MA and Azzabi S: Prognostic factors of advanced stage non-small-cell lung cancer. Tunis Med. 94:360–367. 2016.PubMed/NCBI
4	Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D and Shan L: Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol. 31:9632014. View Article : Google Scholar : PubMed/NCBI
5	Bice T, Li G, Malinchoc M, Lee AS and Gajic O: Incidence and risk factors of recurrent acute lung injury. Crit Care Med. 39:1069–1073. 2011. View Article : Google Scholar : PubMed/NCBI
6	Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ and Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med. 353:1685–1693. 2005. View Article : Google Scholar : PubMed/NCBI
7	Matthay MA, Robriquet L and Fang X: Alveolar epithelium: Role in lung fluid balance and acute lung injury. Proc Am Thorac Soc. 2:pp. 206–213. 2005; View Article : Google Scholar : PubMed/NCBI
8	Smith HW and Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010. View Article : Google Scholar : PubMed/NCBI
9	Feng MY, Liao QJ and Su Q: Advance in research on uPAR and tumor. Int J Pathol Clin Med. 31:49–53. 2011.(In Chinese).
10	Andres SA, Edwards AB and Wittliff JL: Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J Clin Lab Anal. 26:93–103. 2012. View Article : Google Scholar : PubMed/NCBI
11	Thummarati P, Wijitburaphat S, Prasopthum A, Menakongka A, Sripa B, Tohtong R and Suthiphongchai T: High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol. 18:244–250. 2012. View Article : Google Scholar : PubMed/NCBI
12	Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn HJ, Benz C, Eppenberger U and Eppenberger-Castori S: Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol. 24:4245–4253. 2006. View Article : Google Scholar : PubMed/NCBI
13	Mekkawy AH, Morris DL and Pourgholami MH: HAX1 augments cell proliferation, migration, adhesion, and invasion induced by urokinase-type plasminogen activator receptor. J Oncol. 2012:9507492012. View Article : Google Scholar : PubMed/NCBI
14	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
15	Guyot P, Ades AE, Ouwens MJ and Welton NJ: Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 12:92012. View Article : Google Scholar : PubMed/NCBI
16	Panic N, Leoncini E, de Belvis G, Ricciardi W and Boccia S: Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 8:e831382013. View Article : Google Scholar : PubMed/NCBI
17	Almasi CE, Høyer-Hansen G, Christensen IJ, Danø K and Pappot H: Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer. 48:349–355. 2005. View Article : Google Scholar : PubMed/NCBI
18	Almasi CE, Høyer-Hansen G, Christensen IJ and Pappot H: Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. APMIS. 117:755–761. 2009. View Article : Google Scholar : PubMed/NCBI
19	Almasi CE, Christensen IJ, Høyer-Hansen G, Danø K, Pappot H, Dienemann H and Muley T: Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis. Lung Cancer. 74:510–515. 2011. View Article : Google Scholar : PubMed/NCBI
20	Blumenschein GR Jr, Reck M, Fossella F, Stewart DJ, Lathia C and Peña C: Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 10:287–298. 2011–2012. View Article : Google Scholar
21	Su CY, Liu YP, Yang CJ, Lin YF, Chiou J, Chi LH, Lee JJ, Wu AT, Lu PJ, Huang MS and Hsiao M: Plasminogen activator inhibitor-2 plays a leading prognostic role among protease families in non-small cell lung cancer. PLoS One. 10:e01334112015. View Article : Google Scholar : PubMed/NCBI
22	Pappot H: The plasminogen activation system in lung cancer-with special reference to the prognostic role in ‘non-small cell lung cancer’. APMIS Suppl. 92:1–29. 1999.PubMed/NCBI
23	Offersen BV, Pfeiffer P, Andreasen P and Overgaard J: Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis. Lung Cancer. 56:43–50. 2007. View Article : Google Scholar : PubMed/NCBI
24	Pappot H, Pedersen AN, Brünner N and Christensen IJ: The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to prognosis. Lung Cancer. 51:193–200. 2006. View Article : Google Scholar : PubMed/NCBI
25	Pedersen H, Grøndahl-Hansen J, Francis D, Osterlind K, Hansen HH, Danø K and Brünner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54:120–123. 1994.PubMed/NCBI
26	Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP and Foekens JA: The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol. 11:327–332. 2000. View Article : Google Scholar : PubMed/NCBI
27	Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, et al: Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res. 24:4147–4161. 2004.PubMed/NCBI
28	Li Y, Shen Y, Miao Y, Luan Y, Sun B and Qiu X: Co-expression of uPAR and CXCR4 promotes tumor growth and metastasis in small cell lung cancer. Int J Clin Exp Pathol. 7:3771–3780. 2014.PubMed/NCBI
29	Thielemann A, Baszczuk A, Kopczyński P and Kopczyński Z: High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer. Contemp Oncol (Pozn). 17:440–445. 2013.PubMed/NCBI
30	Pulukuri SM, Gorantla B, Dasari VR, Gondi CS and Rao JS: Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells. Mol Cancer Res. 8:1074–1083. 2010. View Article : Google Scholar : PubMed/NCBI
31	de Bock CE and Wang Y: Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 24:13–39. 2004. View Article : Google Scholar : PubMed/NCBI
32	Chiang SP, Cabrera RM and Segall JE: Tumor cell intravasation. Am J Physiol Cell Physiol. 311:C1–C14. 2016. View Article : Google Scholar : PubMed/NCBI
33	Noh H, Hong S and Huang S: Role of urokinase receptor in tumor progression and development. Theranostics. 3:487–495. 2013. View Article : Google Scholar : PubMed/NCBI
34	Montuori N, Pesapane A, Rossi FW, Giudice V, De Paulis A, Selleri C and Ragno P: Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer. Transl Med UniSa. 15:15–21. 2016.PubMed/NCBI